Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696120 | 1.00 | MRGPRX4 (0.66) | MRGPRX4MEN1KMT2AP2RY14NR4A2 | |
| SCHEMBL27158539 | 0.87 | KMT2A (0.55) | MRGPRX4KMT2AALDH1A1GAAMAPT | |
| SCHEMBL20975261 | 0.86 | HPGD (0.60) | MRGPRX4MEN1KMT2AALDH1A1GAA | |
| SCHEMBL31667762 | 0.85 | PTGER1 (0.56) | MRGPRX4MEN1KMT2AP2RY14NR4A2 | |
| SCHEMBL2809626 | 0.84 | MRGPRX4 (0.51) | MRGPRX4MEN1KMT2AALDH1A1GAA | |
| SCHEMBL20515885 | 0.83 | TSHR (0.53) | MRGPRX4MEN1KMT2AALDH1A1GAA | |
| SCHEMBL6563613 | 0.83 | KDM4E (0.64) | MRGPRX4MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9108912 | 0.83 | MRGPRX4 (0.49) | MRGPRX4MEN1KMT2AP2RY14ALDH1A1 | |
| SCHEMBL17966385 | 0.83 | MEN1 (0.63) | MRGPRX4MEN1KMT2ANR4A2NR4A1 | |
| SCHEMBL6204953 | 0.83 | P2RY14 (0.61) | MRGPRX4MEN1KMT2AP2RY14NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20240270758-A1 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| EP-4332105-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| CN-117222650-A | Pyridine or pyrimido-ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| WO-2022228568-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Pheon Therapeutics Ltd. (GB) | 2022-03-31 | — | — | US | disclosed |
| EP-3917924-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Femtogenix Limited (GB) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| CN-106008373-B | Disubstituted bicyclic derivative and its application as efflux pump inhibitor in antibacterial | 山东大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-106008373-A | Disubstituted bicyclic derivative and application thereof as efflux pump inhibitor to anti-microbial | 山东大学 | 2016-10-12 | — | — | CN | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | CCNA1, GNA15, RPS26 | MRGPRX4 722/4885MEN1 1436/4885KMT2A 1875/4885 |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | MRGPRX4 863/4885MEN1 2682/4885KMT2A 1569/4885 |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | MRGPRX4 784/4885MEN1 2698/4885KMT2A 1573/4885 |
| US-20240270758-A1 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | KRAS, NRAS, BRAF | MRGPRX4 2083/4885MEN1 536/4885KMT2A 2951/4885 |
| US-20230302142-A1 | Cytotoxic Agents | ANXA11, ANXA5, HAX1 | MRGPRX4 944/4885MEN1 424/4885KMT2A 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.